FDA Approves Colchicine for Decreasing CV Events
TCTMD,
In a big moment for the “inflammatory hypothesis,” the drug, sold as Lodoco, is the first anti-inflammatory for CVD.
In a big moment for the “inflammatory hypothesis,” the drug, sold as Lodoco, is the first anti-inflammatory for CVD.
An adjuvant anti-inflammatory might offer more protection than additional lipid-lowering, a meta-analysis hints.